Dimension Inx raised $3.175 million to close its series seed financing round. The next-generation biofabrication company was notably supported by KdT Ventures, with Better Ventures and Revolution’s Rise also participating in the seed funding round.
Dimension takes a materials-centric approach to its work. Founded in 2017, the company produces medical-grade materials like Hyperelastic Bone and 3D-Graphene. The company produces metals, alloys, ceramics, and other materials for medical applications. The company’s patented materials design and manufacturing platform creates 3D-printed implants for tissue repair and regeneration. The technology platform overcomes existing challenges in biomaterials and additive manufacturing, which enables important compositional and microstructural features that would otherwise not be commercially feasible.
The new financing will support the commercial development and FDA approval of the company’s first therapeutic implants for facial reconstruction in patients following trauma as well as those with dental malformations due to congenital defects or aging. The company expects to complete pre-clinical studies for FDA 510(k) submission next summer.
“We are incredibly fortunate to partner with investors who support our big vision and appreciate our pragmatic approach to the market, while also understanding the deep science involved in getting there,” said Dimension CEO Dr. Caralynn Nowinski Collens. “We’re looking forward to advancing the science and expanding our strategic partnerships to address a much broader set of surgical applications.”
KdT Ventures is an early-stage science venture investing that helps founders and their companies re-imagine the world at a molecular level. KdT Ventures uses its expertise across multiple disciplines and industries to invest in and support meaningful teams applying computation to chemical and biological systems, including companies like PathAI, Dyno, Solugen, Checkerspot and 54Gene. The seed financing that it has provided to Dimension allows the company to leverage KdT’s connections and knowledge.
“Dimension Inx is the materials specialist of 3D bioprinting,” said Phil Grayeski of KdT Ventures. “Their approach to commercialization and regulatory approval is elegant and pragmatic, with each new product demonstrating the capabilities of their materials and informing the development and validation of their platform across broader and more complex applications in regenerative medicine. We believe the bioprinting world will be built upon the scaffolds Dimension Inx is creating, and we’re thrilled to be supporting this company.”